Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Capsugel, a manufacturer of drug dosage forms and solutions based in New Jersey, has completed the construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its existing research and development (R&D) facility in Bend City, Oregon, US, in June 2015.
It is designed to accommodate future capacity additions and is scheduled for commissioning in late 2015.
Following the acquisition of Bend Research, a division of Capsugel Dosage Form Solutions (DFS) in 2013, Capsugel initiated an investment to add two more commercial-scale spray driers to its Bend site.
The latest SDD addition marks the completion of Capsugel’s $25m investment plan aimed at expanding commercial SDD manufacturing capabilities at its Bend site.
It enables Capsugel to provide integrated services across feasibility, development, late-stage clinical and commercial manufacturing of spray-dried drug product intermediates to its customers.
The expansion created more than 20 new jobs in 2014 and is expected to create an additional 20 full-time positions in the second half of 2015. It has also made Capsugel the biggest integrated pharmaceutical SDD technology owner in North America.
New spray-dried dispersion facility details
The Bend site now houses three commercial-scale spray dryers, one for commercial-scale development and two for cGMP commercial production.
The plant features an innovative dryer design and manufacturing technology and is designed to accommodate high-potency compounds. The new dryers are more flexible and have the capability to generate optimally-engineered particles under the given formulation and therapeutic application.
A commercial wing at the plant allows for the production of registration lots, commercial launch and continued supply of new products from the Bend Research facilities.
Commercial production will be supported by a designed-for-purpose, risk-based quality system in accordance with the principles of ICH Q10 Pharmaceutical Quality System regulations.
Past expansions at the Bend R&D facility
The facility enables testing of spray drying process and contract manufacturing of materials used in clinical trials.
Capsugel installed its first commercial-scale spray dryer at the Bend R&D facility in June 2014. The new pharmaceutical spray dryer (PSD) complemented the existing small and mid-sized spray dryers operating at the plant.
The dryer can also be used for the production of toxicology study supplies and for quality-by-design studies (QbD), whose scale-up aspects can be integrated into spray-dried product development.
It shortens the time taken for development activities in addition to help cut costs and allows for more flexible use of active pharmaceutical ingredients (APIs).
Spray dried dispersion technology and its advantages
Spray drying is a widely-preferred method in the production of thermally-sensitive materials such as pharmaceuticals.
SDD is a single-phase, molecular dispersion of a drug in a polymer matrix that is achieved by dissolving the drug and the polymer in an organic solvent and then spray-drying the solution.
The formulation and process conditions cause the solvent to quickly evaporate from the droplets, preventing separation or crystallisation.
SDD technology helps to increase the bioavailability of poorly water-soluble compounds, and allows for a scalable and controllable manufacturing process.
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…
Bushu Pharmaceuticals unveiled a new expansion programme for its pharmaceutical manufacturing facility in Misato, Japan, in August 2020. With the…
Contract development and manufacturing organisation (CDMO) Sai Life Sciences inaugurated its new research and technology (R&T) centre in Hyderabad, India…